Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
J Martinez-Lopez, R Alonso, SW Wong, R Rios… - Journal of Hematology & …, 2021 - Springer
The assessment of measurable residual disease (MRD) in bone marrow has proven of
prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other …
prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other …
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
BA Derman, AJ Jakubowiak, MA Thompson - Blood Cancer Journal, 2022 - nature.com
… That 60% of respondents reported using MRD status to guide decision making is … on decision
making. It is also notable that the percentage of those using MRD to guide decision making …
making. It is also notable that the percentage of those using MRD to guide decision making …
Enhancing acute myeloid leukemia therapy-monitoring response using residual disease testing as a guide to therapeutic decision-making
B Tomlinson, HM Lazarus - Expert review of hematology, 2017 - Taylor & Francis
… of residual leukemia in the bone marrow. This state has been termed minimal residual disease
(MRD)… , per Goldman and Gale, is ‘measurable residual disease’ [Citation6]. Monitoring of …
(MRD)… , per Goldman and Gale, is ‘measurable residual disease’ [Citation6]. Monitoring of …
Measurable residual disease and decision-making in multiple myeloma
Measurable (or minimal) residual disease (MRD) in multiple myeloma (MM) refers to low
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving, …
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving, …
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
S Faderl, M Talpaz, HM Kantarjian… - Blood, The Journal of …, 1999 - ashpublications.org
… residual disease monitored, can data from such studies be informative? If a threshold of
residual disease … is sustained is found, then residual disease monitoring using quantitative PCR …
residual disease … is sustained is found, then residual disease monitoring using quantitative PCR …
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making
T Lion - Blood, The Journal of the American Society of …, 1999 - ashpublications.org
In the May 1, 1999 issue of Blood, Faderl et al1 discuss the possible clinical role of polymerase
chain reaction (PCR) analysis in the surveillance of residual disease in patients with …
chain reaction (PCR) analysis in the surveillance of residual disease in patients with …
Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease
JM Goldman, JS Kaeda, NCP Cross… - Blood, The Journal …, 1999 - ashpublications.org
… The principal aim of residual disease analysis in patients … that enable the kinetics of residual
disease to be monitored over … the sensitivity with which residual disease can be excluded for …
disease to be monitored over … the sensitivity with which residual disease can be excluded for …
The role of acute myeloid leukemia minimal Residual Disease in regulatory decision-making
D Przepiorka, RA de Claro, R Pazdur - JAMA oncology, 2021 - jamanetwork.com
… Measurable residual disease, as used by Short el al, 1 is … or negative for measurable residual
disease may vary by assay. … or negative in a measurable residual disease assay for AML, it …
disease may vary by assay. … or negative in a measurable residual disease assay for AML, it …
Advancing the minimal residual disease concept in acute myeloid leukemia
P Hokland, HB Ommen, MP Mulé, CS Hourigan - Seminars in hematology, 2015 - Elsevier
… to make important treatment decisions in the 21st century.6, … sensitivity measurements of
residual disease burden in our … the possibility of using minimal residual disease as a surrogate …
residual disease burden in our … the possibility of using minimal residual disease as a surrogate …
[HTML][HTML] Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing …
E Rodríguez-Arbolí, M Othus, C Orvain, LC Zarling… - …, 2023 - ncbi.nlm.nih.gov
… Relative impact of residual cytogenetic abnormalities and flow cytometric measurable
residual disease on outcome after allogeneic hematopoeitic cell transplantation in adult acute …
residual disease on outcome after allogeneic hematopoeitic cell transplantation in adult acute …
相关搜索
- minimal residual disease
- measurable residual disease
- clinical decision making
- residual disease in chronic myelogenous leukemia
- decision making in multiple myeloma
- leukemia patients residual disease
- decision making chronic myelogenous leukemia
- decision making polymerase chain reaction analysis
- polymerase chain reaction residual disease